The European Commission announced its long-awaited Global Health Resilience Initiative on Wednesday. While the policy roadmap aims to support partner countries’ transition toward health sovereignty amid historic aid cuts and shifting geopolitical realities, global health experts are concerned about its heavy reliance on private financing.

As global health gains face a severe threat of reversal from stagnating health system coverage and emerging pathogens, the European Commission’s newly announced strategic guidance seeks to do more than just fill funding gaps. It outlines key priorities and flagship actions designed to fundamentally revamp the multilateral health architecture and support partner countries’ transition toward health sovereignty amid a rapidly changing funding landscape.

The proposed strategy, issued in a formal communication to the EU parliament and the member states, reinforces the pivot away from fragmented development assistance. Instead of relying solely on traditional grants, European policymakers intend to use “de-risking” tools and blended finance – combining public funds with loans and guarantees – to help partner countries build self-sustaining sovereignty for their national health systems.

“Europe gains from stronger supply chains,” said European Commissioner for International Partnerships Jozef Síkela at a press conference on Wednesday. “Our partners gain from investments in local infrastructure, skills and jobs based on partnership with EU companies.”

Beyond immediate crisis management, the new initiative deliberately lays down a strategic, long-term pathway for European funding. It essentially sets the broad strategic strokes that will shape the global health priorities of the European Union’s next long-term Multiannual Financial Framework, which begins in 2028.

Recommitment to a leaner multilateral system

Ahead of the upcoming World Health Assembly in Geneva next week, the Global Health Resilience Initiative is a recommitment to the World Health Organization (WHO). However, to overcome the deep fragmentation of the global health landscape caused by competing funds, the Commission is actively advocating for a leaner, more streamlined institutional architecture – which now includes not only WHO, but UNAIDs, UNICEF and other health-related bodies under the UN umbrella.

“We need a more effective and less fragmented global health architecture. There are too many players, too many overlapping mandates,” said EU-Commissioner Síkela.

To better coordinate these efforts, the strategic proposal aims to significantly step up alignment between European member states before major international replenishments and key financing milestones. This approach involves creating a comprehensive map of all European global health investments to actively eliminate redundancies and boost donor synergies.

This unified diplomatic front will be supported by a novel global health and resilience tracker. Developed in collaboration with the World Bank, the Organisation for Economic Co-operation and Development (OECD), and the WHO, this tool will initially focus on pandemic preparedness, prevention, and response by mapping both the domestic spending of partners and the international support they receive.

Over time, this tracking will be progressively expanded to cover broader global health priorities. The tool is explicitly designed to increase the transparency and accountability of global health security financing.

Fostering private investments and EU interests

Driven by a historic collapse in Official Development Assistance (ODA), European policymakers are moving beyond traditional aid to finance this sweeping agenda of infrastructural upgrades, environmental monitoring, and digital defences.

To bridge this massive financial shortfall, the Global Health Resilience Initiative leverages the EU’s external action tool, the Global Gateway, to mobilise up to €300 billion in investments. By shifting away from direct grants, the strategy relies on blended finance – using loans and guarantees – to de-risk and incentivise substantial private sector involvement in emerging economies.

According to Commissioner Síkela, this approach has already successfully channelled over €6 billion specifically into health projects by the end of 2025. The flagship initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+) is part of this and exemplifies the strategy, having directed roughly €2 billion toward building pharmaceutical manufacturing capacities across the African continent, including investments in South Africa and Senegal.

The Communication signals the Commission’s intent to formalise this approach within the EU’s executive branch, cementing a policy shift that explicitly aligns international development with European economic security and competitiveness. In practice, this means that while partner countries receive investments to build their resilience, European pharmaceutical and biotech firms are now strategically positioned to access these expanding, rules-based markets as a complementary alternative to relying solely on exports.

“Global health is not immune to the fierce competition, coercive power politics, and information manipulation that influence international relations,” warned Kaja Kallas, High Representative for Foreign Affairs and Security Policy. “While some pull back from multilateral organisations that protect global health, the EU is stepping up with more support.”

Upgrading detection capabilities and implementing a ‘One Health’ approach

To complement these financial tracking and governance reforms, the Global Health Resilience Initiative introduces major infrastructural upgrades aimed at rapid crisis response. The Commission wants to support the establishment of an EU Therapeutics Hub and a parallel EU Diagnostics Hub to ensure the rapid deployment of essential medical countermeasures, with a specific focus on equitable access for vulnerable and minority populations. Further details are yet to be published.

Additionally, the Commission announced that early detection capabilities will receive a boost through investments in international epidemiological surveillance networks, including advanced wastewater and environmental monitoring that detects pathogens well before clinical alarms trigger. By partnering with regional public health institutes, the EU hopes to close the vast data reporting gaps that currently obscure the true scale of mortality worldwide.

By formally embedding the “One Health” principle into the European external agenda and recognising the intrinsic connection between human health, animal health, and resilient natural ecosystems, the strategy shifts focus toward “deep prevention” – the ability to identify and address environmental threats before pathogens cross from animals to humans. This aligns directly with the EU’s 2022 Global Health Strategy, effectively positioning the new Resilience Initiative as the financial muscle needed to deliver on those earlier promises.

Acknowledging that climate change, biodiversity loss, and environmental degradation drive these dangerous zoonotic spillovers, the bloc announced it would be pushing for stronger environmental safeguards within multilateral treaties. This holistic, root-cause approach also extends to combatting antimicrobial resistance through the prudent use of antimicrobials and new clinical research.

Critics concerned about risks of market-based health financing

While the initiative rightly acknowledges the way in which institutional fragmentation can exacerbate, rather than address, global health threats, civil society critics were quick to note that the EU’s new initiative largely ignores the political drivers of health inequality. Critics warn that increasing the role of private corporations in the health systems of low-income countries could also fuel higher health care costs and inequalities – and undermine the goal of  ‘health sovereignty’.

“The strong focus on expertise, investments and supply chains points more towards a model in which dependencies are reorganised rather than fundamentally overcome,” explains Karolin Seitz, Program Director of the global health and human rights program at Global Policy Forum Europe, in a statement to Health Policy Watch. She notes that while promoting “health sovereignty” is commendable, it remains unclear how much real fiscal and political policy space low- and middle-income countries will actually gain.

Seitz cautions that the Commission’s reliance on market-based mechanisms, such as blended finance through the Global Gateway, frequently socialises financial risks while securing guaranteed returns for private investors using public money. Rather than offering innovative solutions, these models can impose significant long-term costs on the public budgets of vulnerable nations, she warns.

Furthermore, the EU’s strategy frames global health primarily as an issue of efficient governance and capital mobilisation, neglecting root causes like debt crises, unequal patent rules, and local tax evasion. Genuine health sovereignty, Seitz argues, requires structural reforms and sufficient public fiscal space – issues the EU’s approach currently leaves largely unaddressed.

Record ODA Cuts: Top Donors Slash Aid as Global Health Risks Grow

Image Credits: EU/Bogdan Hoyaux, Felix Sassmannshausen/HPW, WHO , Global Policy Forum Europe..